In this study, we characterized the regulatory potential of memory B cells (CD19+CD20+CD27+) differentially expressing TIM-1 and TIGIT in PBMCs from MS patients compared to those from healthy controls. This evidence concerns the gene CD19 and myeloid sarcoma.